Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-79635322 Combinations in Multiple Myeloma, AL Amyloidosis, and Smoldering Multiple Myeloma
NCT06768489Phase 1Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2024
- Primary completion
- Jan 2029
- Modality
- Trispecific Antibodies, T-cell Engagers
- Countries
- 5
01
Overview
Phase 1, open-label trial of ramantamig in multiple myeloma (MM), immunoglobulin light chain amyloidosis and smoldering multiple myeloma (SMM) (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Dose-limiting Toxicity at 28 days, Adverse Events and 1 more. Started Dec 2024; status: recruiting.
02
Drugs
ramantamig
03
Conditions
multiple myeloma (MM)immunoglobulin light chain amyloidosissmoldering multiple myeloma (SMM)
Beyond the preview
Go deeper on NCT06768489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06768489.